Research ArticleInfectious Disease

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

See allHide authors and affiliations

Science Translational Medicine  03 May 2017:
Vol. 9, Issue 388, eaaj1928
DOI: 10.1126/scitranslmed.aaj1928

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Pan-RSV prophylaxis

The common respiratory syncytial virus (RSV) can progress to a very dangerous lower respiratory infection in some infants. A protective monoclonal antibody is available but is not recommended for general use. Zhu et al. describe the selection and optimization of a human monoclonal antibody able to neutralize a wide array of RSV A and B viruses and protect cotton rats at lower doses than the currently approved antibody. The antibody was optimized to persist in circulation, and data indicate that infants could be given a single dose and be protected for the entirety of the RSV season. If administered widely, this antibody could potentially prevent the hospitalization of thousands of children each year.

View Full Text